prof. dr. H.J. (Hidde) Haisma

Professor Therapeutic Gene Modulation

prof. dr. H.J. (Hidde) Haisma
Telephone:
+31 50 36 38174 (Secretariat)
E-mail:
h.j.haisma rug.nl

Research

Postal address:
A Deusinglaan
1
Gebouw 3211, ruimte 0306
Groningen
Netherlands
Phone: +31 50 363 6865
  1. 2002
  2. van der Poel, HG., Molenaar, B., van Beusechem, VW., Haisma, HJ., Rodriguez, R., Curiel, DT., & Gerritsen, WR. (2002). Epidermal growth factor receptor targeting of replication competent adenovirus enhances cytotoxicity in bladder cancer. Journal of Urology, 168(1), 266-272.
  3. Arafat, WO., Gomez-Navarro, J., Buchsbaum, DJ., Xiang, J., Casado, E., Barker, SD., ... Curiel, DT. (2002). Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv. Gene Therapy, 9(4), 256-262. https://doi.org/10.1038/sj.gt.3301639
  4. Witlox, M. A., van Beusechem, V. W., Grill, J., Haisma, H. J., Schaap, G., Bras, J., ... Wuisman, P. I. (2002). Epidermal growth factor receptor targeting enhances adenoviral vector based suicide gene therapy of osteosarcoma. J Gene Med, 4(5), 510 - 516. https://doi.org/10.1002/jgm.308
  5. de Graaf, M., van der Meulen-Muileman, I. H., Pinedo, H. M., & Haisma, H. J. (2002). 34 Expression of scFvs and scFv Fusion Proteins in Eukaryotic Cells. In Antibody Phage Display (pp. 379-387). Springer.
  6. 2001
  7. van Beusechem, VW., Grill, J., Mastenbroek, DCJ., Haisma, HJ., Wickham, TJ., Roelvink, PW., ... Gerritsen, WR. (2001). Highly specific adenovirus vectors for targeted cancer gene therapy. Cancer Gene Therapy, 8(9), 688-689.
  8. de Gruijl, TD., van den Eertwegh, AJM., Haisma, HJ., Curiel, DT., Gerritsen, WR., Pinedo, HM., & Scheper, RJ. (2001). Targeted adenoviral transduction and activation of cutaneous dendritic cells: studies in a human skin explant model. Cancer Gene Therapy, 8(9), 685-685.
  9. De Graaf, M., Van Veen, IC., Van Der Meulen-Muileman, IH., Gerritsen, WR., Pinedo, HM., & Haisma, HJ. (2001). Cloning and characterization of human liver cytosolic beta-glycosidase. Biochemical Journal, 356, 907-910.
  10. Heideman, DAM., Snijders, PJF., Craanen, ME., Bloemena, E., Meijer, CJLM., Meuwissen, SGM., ... Gerritsen, WR. (2001). Selective gene delivery toward gastric and esophageal adenocarcinoma cells via EpCAM-targeted adenoviral vectors. Cancer Gene Therapy, 8(5), 342-351.
  11. Heideman, DAM., Snijders, PJF., Craanen, ME., Bloemena, E., Meijer, CJLM., Meuwissen, SGM., ... Gerritsen, WR. (2001). Targeting of adenoviral vectors towards gastric and esophageal adenocarcinoma cells. Gastroenterology, 120(5), A614.
  12. Grill, J., Van Beusechem, VW., Van de Valk, P., Dirven, CMF., Leonhart, A., Pherai, DS., ... Gerritsen, WR. (2001). Combined targeting of adenoviruses to integrins and epidermal growth factor receptors increases gene transfer into primary glioma cells and spheroids. Clinical Cancer Research, 7(3), 641-650.
  13. 2000
  14. van Beusechem, VW., van Rijswijk, ALCT., van Es, HHG., Haisma, HJ., Pinedo, HM., & Gerritsen, WR. (2000). Recombinant adenovirus vectors with knobless fibers for targeted gene transfer. Gene Therapy, 7(22), 1940-1946.
  15. Haisma, HJ., van Beusechem, VW., Curiel, DT., Pinedo, HM., & Gerritsen, WR. (2000). Targeted enzymes for molecular chemotherapy. Cancer Gene Therapy, 7(8), 1208-1208.
  16. Haisma, HJ., Grill, J., Curiel, DT., Hoogeland, S., van Beusechem, VW., Pinedo, HM., & Gerritsen, WR. (2000). Targeting of adenoviral vectors through a bispecific single-chain antibody. Cancer Gene Therapy, 7(6), 901-904.
  17. Heideman, DA., Snijders, PJ., Craanen, ME., Bloemena, E., van Beusechem, VW., Pinedo, HM., ... Gerritsen, WR. (2000). EpCAM is a marker for (pre-) malignant lesions of the stomach, and a good target for specific gene transfer towards gastric carcinoma cells. Gastroenterology, 118(4), A704-A704.
  18. 1999
  19. Bangma, CH., Kraaij, R., van Rijswijk, A., Haisma, HJ., van Beusechem, V. W., & Gerritsen, W. (1999). Transductional targeting of adenoviral vectors to prostate cancer in vitro. Prostate Cancer and Prostatic Diseases, 2, S5-S5.
  20. Leenders, RGG., Damen, EWP., Bijsterveld, EJA., Scheeren, HW., Houba, PHJ., van der Meulen-Muileman, IH., ... Haisma, HJ. (1999). Novel anthracycline-spacer-beta-glucuronide, -beta-glucoside, and -beta-galactoside prodrugs for application in selective chemotherapy. Bioorganic & Medicinal Chemistry, 7(8), 1597-1610.
  21. Haisma, HJ., Pinedo, HM., van Rijswijk, A., van der Muelen-Muileman, N. V., Sosnowski, BA., Ying, W., ... Curiel, DT. (1999). Tumor-specific gene transfer via an adenoviral vector targeted to the pan-carcinoma antigen EpCAM. Gene Therapy, 6(8), 1469-1474.
  22. Houba, PHJ., Boven, E., van der Meulen-Muileman, IH., Leenders, RGG., Scheeren, JW., Pinedo, HM., & Haisma, HJ. (1999). Distribution and pharmacokinetics of the prodrug daunorubicin-GA3 in nude mice bearing human ovarian cancer xenografts. Biochemical Pharmacology, 57(6), 673-680.
  23. 1998
  24. Houba, PHJ., Boven, E., Erkelens, CAM., Leenders, RGG., Scheeren, JW., Pinedo, HM., & Haisma, HJ. (1998). The efficacy of the anthracycline prodrug daunorubicin-GA3 in human ovarian cancer xenografts. British Jounal of Cancer, 78(12), 1600-1606. https://doi.org/10.1038/bjc.1998.729
  25. Haisma, HJ., Sernee, MF., Hooijberg, E., Brakenhoff, RH., van den Meulen-Mulleman, IH., Pinedo, HM., & Boven, E. (1998). Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human beta-glucuronidase for antibody-directed enzyme prodrug therapy. Blood, 92(1), 184-190.
  26. de Bont, H. BA., Leenders, R. GG., Scheeren, J. W., Haisma, H. J., & de Vos, D. (1998). IPC No. C07H 13/ 12 A I. Paclitaxel prodrugs, method for preparation as well as their use in selective chemotherapy. (Patent No. US5760072).
  27. Damen, E. WP., de Vos, D., Haisma, H. J., Houba, P. HJ., Leenders, R. GG., & Scheeren, J. W. (1998, Jan 1). Anthracycline prodrugs, method for preparation as well as their use in selective chemotherapy. Google Patents.
  28. Houba, PHJ., Boven, E., Leenders, RGG., van der Meulen-Mulleman, IH., Scheeren, JW., Pinedo, HM., & Haisma, HJ. (1998). Tumor selective activation of a doxorubicin prodrug (DOX-GA3) in human ovarian cancer xenografts. Annals of Oncology, 9, 51-51.
  29. 1997
  30. Meijs, WE., Haisma, HJ., Klok, RP., vanGog, FB., Kievit, E., Pinedo, HM., & Herscheid, JDM. (1997). Zirconium-labeled monoclonal antibodies and their distribution in tumor-bearing nude mice. Journal of Nuclear Medicine, 38(1), 112-118.
  31. Haisma, HJ., Pinedo, HM., vandeMeulenMuileman, IH., Houba, PHJ., Leenders, RGG., Scheeren, JW., & Boven, E. (1997). Daunorubicin-GA3, a novel prodrug for use in gene therapy. Cancer Gene Therapy, 4(5), 307-307.
  32. 1996
  33. Meijs, WE., Haisma, HJ., VanderSchors, R., Wijbrandts, R., VandenOever, K., Klok, RP., ... Herscheid, JDM. (1996). A facile method for the labeling of proteins with zirconium isotopes. Nuclear Medicine and Biology, 23(4), 439-448.
  34. 1995
  35. Haisma, H., VANMUIJEN, M., SCHEFFER, G., SCHEPER, RJ., PINEDO, HM., & BOVEN, E. (1995). A MONOCLONAL-ANTIBODY AGAINST HUMAN BETA-GLUCURONIDASE FOR APPLICATION IN ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY. Hybridoma, 14(4), 377-382.
  36. HAISMA, HJ., & Haisma, H. (1995). MAB-105 ANTI-HUMAN BETA-GLUCURONIDASE. Hybridoma, 14(4), 402-402.
  37. LEENDERS, RGG., GERRITS, KAA., RUIJTENBEEK, R., SCHEEREN, HW., Haisma, H., & BOVEN, E. (1995). BETA-GLUCURONYL CARBAMATE BASED PRO-MOIETIES DESIGNED FOR PRODRUGS IN ADEPT. Tetrahedron Letters, 36(10), 1701-1704.

ID: 207456